Study Stopped
The funding agency, DoD, determined that the study could not meet its enrollment numbers by the end of the grant
Cardiovascular Risk Markers in Veterans With Post Traumatic Stress Disorder
CVMarkers
1 other identifier
observational
13
1 country
1
Brief Summary
This is an observational study designed to determine whether veterans with PTSD have a higher risk of heart disease than those without PTSD. Cardiovascular risk will be assessed by interview and review of medical records, carotid artery ultrasound, and blood tests measuring markers of inflammation. Study participation is approximately 6 months. The eligible study population is veterans of Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), age 28 through 38 years.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Apr 2012
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2012
CompletedFirst Submitted
Initial submission to the registry
June 20, 2012
CompletedFirst Posted
Study publicly available on registry
July 26, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2013
CompletedApril 29, 2013
April 1, 2013
9 months
June 20, 2012
April 25, 2013
Conditions
Outcome Measures
Primary Outcomes (5)
Recruitment methods feasibility
Comparison of the number of participants per month recruited from medical providers (with/without PTSD) vs. response to recruitment fliers (with/without PTSD) in the first 12 months of the study. Selection bias to be determined by looking at differences in age and co-morbid illnesses.
12 months
Completion of structured diagnostic interview within 2hrs.
Completion of Clinician Assessed PTSD Scale (CAPS), Alcohol Use Disorders Identification Test-Consumption (AUDIT-C), Patient Health Questionnaire-9 (PHQ-9), Pittsburgh Sleep Quality Index (PSQI), INTRuST Uniformed Data Set, and Family History of heart disease, within 2hrs.
12 months
Ability to schedule Carotid Intima-Media Thickness (CIMT) ultrasound in the Vascular Lab at VA San Diego Healthcare Systems, within 4 months of enrollment
Determining whether the Vascular Lab has the capacity for a larger clinical study will be informative in planning larger prospective studies.
18months
Time from CIMT completion to completion of clinical read.
Rate of clinical read will help in determining adequate staffing requirements for a larger study.
18months
Completion of serum lab measurements.
18months
Secondary Outcomes (2)
Carotid Intimal Medial Thickness (CIMT) measurement
Within 4 months of subject recruitment
Cardiovascular Disease Biomarkers
Within 6 months of subject recruitment
Study Arms (2)
Veterans with a history of PTSD
Veterans without a history of PTSD
Eligibility Criteria
OIF and OEF veterans within the VASDHS, who are between 28 and 38 years of age inclusively
You may qualify if:
- OEF/OIF veterans at the VASDHS
- Between 28 and 38 years of age
- Willing to complete structured diagnostic interview for PTSD, CIMT ultrasound and blood test
- Willing to have a review of their medical records
- Able to give informed consent
- Have a negative urine pregnancy test, if a woman of child-bearing age
You may not qualify if:
- History of schizophrenia, other neurocognitive illness (including severe TBI by INTRuST criteria)) or active alcohol and/or drug abuse determined by chart review, interview or AUDIT-C score
- Inability to complete study tests within 18 months of study start
- Pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
VASDHS
San Diego, California, 92161, United States
Biospecimen
For the assessment of CVD risk, high-sensitivity CRP (hs-CRP) measurements will be used. Standard assays detect 1,000 fold increases in CRP in response to infection or inflammation; these high levels cannot be used to stratify with respect to CVD risk. Hs-CRP, however, measurement can detect CRP levels as low as 0.5 mg/L. Though mainly used for research purposes, high-sensitivity IL-6 assays are also able to discriminate IL-6 levels within the normal range for CVD risk stratification. Both CRP and IL-6 levels will be analyzed as continuous quantitative traits. Though no DNA analysis is planned for this study, subjects are asked if they are willing to have their samples banked for future research.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Vibha Bhatnagar, MD
University of California, San Diego
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 20, 2012
First Posted
July 26, 2012
Study Start
April 1, 2012
Primary Completion
January 1, 2013
Study Completion
January 1, 2013
Last Updated
April 29, 2013
Record last verified: 2013-04